SPOTLIGHT: Panel advises against long-term data
An FDA advisory panel is recommending that the makers of drugs used to treat depression should not have to provide long-term data on their effectiveness. The FDA had been considering major changes in the data that would be needed to gain approval for a drug to treat depression. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
